<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582490</url>
  </required_header>
  <id_info>
    <org_study_id>MA402S23B901</org_study_id>
    <nct_id>NCT01582490</nct_id>
  </id_info>
  <brief_title>Study of EXPAREL in Patients Undergoing Breast Augmentation</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of EXPARELÂ® (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, prospective, open-label, non-randomized, sequential study with two
      treatment groups differing only in the technique used for EXPAREL administration
      (instillation or infiltration).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject underwent bilateral augmentation mammoplasty and received the same dose of
      EXPAREL. This primary objective of this study was to assess the efficacy of EXPAREL when
      administered via infiltration versus instillation as part of bilateral augmentation
      mammoplasty. The secondary objectives were to further assess other efficacy measures and the
      safety profile of EXPAREL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Analgesia</measure>
    <time_frame>10 days</time_frame>
    <description>The primary outcome measure is the duration of analgesia, measured by the time (hours) from the end surgery to the subject's first postsurgical opioid administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Postsurgical Opioid Consumption in the Surgical Center</measure>
    <time_frame>10 days</time_frame>
    <description>Total amount of opioids (morphine-equivalent mg) administered postsurgically in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Assessment Upon Waking in the PACU</measure>
    <time_frame>Upon waking in the PACO post surgery</time_frame>
    <description>Subject-reported pain assessment upon waking in the PACU on a scale of 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Assessment at the Time of Hospital Discharge</measure>
    <time_frame>At the time of hospital discharge</time_frame>
    <description>Subject-reported pain assessment at the time of hospital discharge (assessed an average of 3.11 hours after surgery for the Instillation group and 3.20 hours after surgery for the Infiltration group) on a scale from 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge Being Written</measure>
    <time_frame>At the time of hospital discharge</time_frame>
    <description>The time (hours) to the hospital discharge being written for subjects in each group,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Opioid-Related Adverse Events</measure>
    <time_frame>Through 10 Days Post Surgery</time_frame>
    <description>The incidence of adverse events that were assessed as opioid-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Hospital Discharge</measure>
    <time_frame>At the time of hospital discharge</time_frame>
    <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Day 10</measure>
    <time_frame>Day 10 after surgery</time_frame>
    <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Mammoplasty</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Infiltration - EXPAREL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Instillation - EXPAREL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Instillation - EXPAREL</intervention_name>
    <description>Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.</description>
    <arm_group_label>Infiltration - EXPAREL</arm_group_label>
    <other_name>bupivacaine liposomal injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infiltration - EXPAREL</intervention_name>
    <description>IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.</description>
    <arm_group_label>Instillation - EXPAREL</arm_group_label>
    <other_name>bupivacaine liposomal injectable suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 18-75 years of age inclusive.

          -  American Society of Anesthesiologists (ASA) physical status 1-3.

          -  Undergoing bilateral augmentation mammoplasty without any concurrent surgical
             procedure(s).

          -  Physically and mentally able to participate in the study and complete all study
             assessments.

          -  Able to give fully informed consent to participate in this study after demonstrating a
             good understanding of the risks and benefits of the study components.

        Exclusion Criteria:

          -  History of hypersensitivity or idiosyncratic reactions to amide-type local
             anesthetics.

          -  Any subject whose anatomy or surgical procedure might, in the opinion of the
             Investigator, preclude the potential successful local administration of EXPAREL.

          -  Subjects currently pregnant or who may become pregnant during the course of the study.

          -  Any subject who in the opinion of the Investigator might be harmed or be a poor
             candidate for participation in the study.

          -  Subjects who have received any investigational drug within 30 days prior to study drug
             administration, or planned administration of another investigational product or
             procedure during their participation in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Del Vecchio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steward St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <results_first_submitted>April 29, 2014</results_first_submitted>
  <results_first_submitted_qc>May 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>May 31, 2014</last_update_submitted>
  <last_update_submitted_qc>May 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mammoplasty</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infiltration - EXPAREL</title>
          <description>Subjects received EXPAREL 266 mg via infiltration.</description>
        </group>
        <group group_id="P2">
          <title>Instillation - EXPAREL</title>
          <description>Subjects received EXPAREL 266 mg via instillation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>19 subjects were enrolled, 9 in the Infiltration - EXPAREL group and 10 in the Instillation - EXPAREL group.</population>
      <group_list>
        <group group_id="B1">
          <title>Infiltration - EXPAREL</title>
          <description>Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
Instillation - EXPAREL: Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.</description>
        </group>
        <group group_id="B2">
          <title>Instillation - EXPAREL</title>
          <description>Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
Infiltration - EXPAREL: IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="7.25"/>
                    <measurement group_id="B2" value="29.7" spread="11.41"/>
                    <measurement group_id="B3" value="28.8" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Classification</title>
          <description>There were 19 subjects enrolled. 8 subjects in the Infiltration - EXPAREL group were in the safety analysis set. 10 subjects in the Instillation - EXPAREL group were in the safety analysis set. ASA Class 1 is defined as a normal healthy subject; ASA Class 2 is defined as a subject with mild systemic disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA Class 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Analgesia</title>
        <description>The primary outcome measure is the duration of analgesia, measured by the time (hours) from the end surgery to the subject's first postsurgical opioid administration.</description>
        <time_frame>10 days</time_frame>
        <population>Of the 8 subjects in the Infiltration - EXPAREL group (efficacy analysis set), 5 were censored, leaving 3 subjects who were administered an opioid. Of the 9 subjects in the Instillation - EXPAREL group (efficacy analysis set), 7 were censored, leaving 2 subjects who were administered an opioid.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received EXPAREL 266 mg via infiltration.</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received EXPAREL 266 mg via instillation.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Analgesia</title>
          <description>The primary outcome measure is the duration of analgesia, measured by the time (hours) from the end surgery to the subject's first postsurgical opioid administration.</description>
          <population>Of the 8 subjects in the Infiltration - EXPAREL group (efficacy analysis set), 5 were censored, leaving 3 subjects who were administered an opioid. Of the 9 subjects in the Instillation - EXPAREL group (efficacy analysis set), 7 were censored, leaving 2 subjects who were administered an opioid.</population>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum time to postsurgical opioid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum time to postsurgical opioid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28"/>
                    <measurement group_id="O2" value="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Postsurgical Opioid Consumption in the Surgical Center</title>
        <description>Total amount of opioids (morphine-equivalent mg) administered postsurgically in each group.</description>
        <time_frame>10 days</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received EXPAREL 266 mg via infiltration.</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received EXPAREL 266 mg via instillation.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Postsurgical Opioid Consumption in the Surgical Center</title>
          <description>Total amount of opioids (morphine-equivalent mg) administered postsurgically in each group.</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="6.26"/>
                    <measurement group_id="O2" value="3.0" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Assessment Upon Waking in the PACU</title>
        <description>Subject-reported pain assessment upon waking in the PACU on a scale of 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
        <time_frame>Upon waking in the PACO post surgery</time_frame>
        <population>There were 9 subjects in the Infiltration - EXPAREL efficacy analysis set and 8 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Assessment Upon Waking in the PACU</title>
          <description>Subject-reported pain assessment upon waking in the PACU on a scale of 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
          <population>There were 9 subjects in the Infiltration - EXPAREL efficacy analysis set and 8 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.98"/>
                    <measurement group_id="O2" value="3.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Assessment at the Time of Hospital Discharge</title>
        <description>Subject-reported pain assessment at the time of hospital discharge (assessed an average of 3.11 hours after surgery for the Instillation group and 3.20 hours after surgery for the Infiltration group) on a scale from 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
        <time_frame>At the time of hospital discharge</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Assessment at the Time of Hospital Discharge</title>
          <description>Subject-reported pain assessment at the time of hospital discharge (assessed an average of 3.11 hours after surgery for the Instillation group and 3.20 hours after surgery for the Infiltration group) on a scale from 0 to 10 where 0 = no pain and 10 = worst possible pain.</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.39"/>
                    <measurement group_id="O2" value="3.4" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge Being Written</title>
        <description>The time (hours) to the hospital discharge being written for subjects in each group,</description>
        <time_frame>At the time of hospital discharge</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge Being Written</title>
          <description>The time (hours) to the hospital discharge being written for subjects in each group,</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.941"/>
                    <measurement group_id="O2" value="3.11" spread="1.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Opioid-Related Adverse Events</title>
        <description>The incidence of adverse events that were assessed as opioid-related</description>
        <time_frame>Through 10 Days Post Surgery</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Opioid-Related Adverse Events</title>
          <description>The incidence of adverse events that were assessed as opioid-related</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Hospital Discharge</title>
        <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
        <time_frame>At the time of hospital discharge</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Hospital Discharge</title>
          <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Satisfied nor Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Day 10</title>
        <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
        <time_frame>Day 10 after surgery</time_frame>
        <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Infiltration - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via infiltration</description>
          </group>
          <group group_id="O2">
            <title>Instillation - EXPAREL</title>
            <description>Subjects received 266 mg EXPAREL via instillation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control at Day 10</title>
          <description>Subject-reported satisfaction with postsurgical pain control in the categories of &quot;extremely dissatisfied,&quot; &quot;dissatisfied,&quot; &quot;neither satisfied nor dissatisfied,&quot; &quot;satisfied,&quot; and &quot;extremely satisfied.&quot;</description>
          <population>There were 8 subjects in the Infiltration - EXPAREL efficacy analysis set and 9 subjects in the Instillation - EXPAREL efficacy analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extremely Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Satisfied nor Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From surgery through Day 10.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infiltration - EXPAREL</title>
          <description>Subjects received 266 mg EXPAREL via infiltration</description>
        </group>
        <group group_id="E2">
          <title>Instillation - EXPAREL</title>
          <description>Subjects received 266 mg EXPAREL via instillation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erol Onel, MD</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>858-625-2424</phone>
      <email>erol.onel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

